ANTI-VEGF-ANTIBODY AND ITS PHARMACEUTICAL COMPOSITION FOR PREVENTION, DIAGNOSTICS OR TREATMENT OF CANCER OR ANGIOGENESIS-RELATED DISEASE Russian patent published in 2018 - IPC C07K16/22 C12N15/13 C12N15/63 C12N5/10 A61K39/395 A61P9/00 A61P35/00 G01N33/53 

FIELD: medicine.

SUBSTANCE: antibody is proposed that binds to a human and mouse vascular endothelial A (VEGF-A) growth factor, as well as an antigen-binding fragment of such an antibody. DNAs encoding the variable regions of the light and heavy chains of the antibody or its antigen-binding fragment are also contemplated; expression vectors and an animal cell line for production of an antibody or antigen-binding fragment thereof. In addition, pharmaceutical compositions are described for prevention or treatment of an angiogenesis-related disease caused by VEGF-A overexpression and for diagnosis of such a disease. The proposed antibody is capable of inhibiting VEGF-A binding to the KDR receptor (VEGFR2) and inhibiting the proliferation and permeability of human umbilical vein endothelial cells (HUVEC).

EFFECT: invention can find further application in treatment of diseases associated with VEGF-A, including cancer.

18 cl, 13 dwg, 6 tbl, 15 ex